BioSpace News Archive

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Shiraz Ladiwala to its Board of Directors, effective October 28, 2021.

Akebia Therapeutics, Inc and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka), today announced that Otsuka Pharmaceutical Netherlands B.V. has submitted an initial marketing authorization application (MAA) to the European Medicines Agency for vadadustat,

Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that in conjunction with Breast Cancer Awareness month, which takes place each October, it has launched its new website for the Aware® at-home breast self-exam pad. Breast cancer is the most commonly-diagnosed cancer in women.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company’s lead product candidate, will be presented in eight poster presentations at the Neuroscience Education Institute (NEI) Congress.

Business France and the Galien Foundation are pleased to announce the winners of the eighth edition of the Galien Medstartup Awards.

In collaboration with Linköping University and Virginia Commonwealth University, AMRA researchers found that adverse muscle composition—defined by low muscle volume coupled with high muscle fat infiltration—was a strong and independent predictor of all-cause mortality.

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the third quarter 2021 after the stock market close on Monday, November 8, 2021.

Immunovia AB announced that Thomas King, MD, PhD, Medical Director of Immunovia, Inc. was invited to present to the U.S. National Cancer Institute Pancreatic Cancer Detection Consortium as a keynote speaker at their upcoming Steering Committee Meeting, taking place virtually on December 13-14, 2021.

Vaso Corporation announces the amendment of the sales representation agreement between its subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, and GE Healthcare, the healthcare business unit of General Electric Company, originally signed on May 19, 2010.

An increasing number of studies suggest a link between a neighborhood’s built environment and the likelihood that its residents will develop chronic diseases such as heart disease, type 2 diabetes and certain types of cancers.